Liuting Yu
Shenzhen, 518107, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia.
Journal: Cell reports. Medicine
Published: November 21, 2024
Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia.
Journal: Medical oncology (Northwood, London, England)
Published: September 03, 2024
Tubular epithelial cell-derived Flt3L is required for type 1 conventional dendritic cell (cDC1) activation and expansion in promoting the recovery in acute kidney injury.
Journal: Journal of advanced research
Published: July 24, 2024
Targeting Glutamine Metabolism as an Attractive Therapeutic Strategy for Acute Myeloid Leukemia.
Journal: Current treatment options in oncology
Published: April 22, 2023
miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia.
Journal: Cell death discovery
Published: April 12, 2023
Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
Journal: Biochemical pharmacology
Published: February 23, 2023
Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML.
Journal: Experimental hematology & oncology
Published: October 29, 2022
The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia.
Journal: Frontiers in oncology
Published: April 29, 2022
Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor.
Journal: BMC medicine
Published: February 07, 2022
Last Updated: 09/26/2026